An interventional study of Furosemide and Placebo in Respiratory Morbidity, sponsored by Makassed General Hospital. Completed at 1 site in Lebanon. Open to participants aged 1 Day to 1 Day. Per ClinicalTrials.gov, last updated 2022-08-30.
Sponsored by Makassed General Hospital · Not applicable, Interventional, and Other
This is a randomized double blind clinical trial in which newborns with suspected Transient tachypnea of the newborn (TTN) will receive either furosemide or normal saline by nebulizer every 6 hours for 24 hours.
Exclusion Criteria:
Patients will receive nebulised furosemide
Other: Furosemide
Patients will receive nebulised 0.9% saline
Other: Placebo
Patients will receive nebulised furosemide solution 1 mg/kg
Patients will receive nebulised 0.9% saline
Percentage of patients with respiratory morbidity
Neonatal respiratory morbidity will be assessed through oxygen saturation, respiratory rate and duration on Continuous positive airway pressure (CPAP)
Time frame: 24 hours
Length of hospital stay
Duration of hospital stay in days
Time frame: 15 days
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Makassed General Hospital